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ABSTRACT 
Objective: Oral metoprolol tartrate has a short elimination half-life (2-3h) and low bioavailability undergoes extensive first-pass metabolism and 
frequent dosing. The aim of the present investigation was to formulate, develop and evaluate metoprolol tartrate transdermal patches using various 
synthetic and natural penetration enhancers. 
Methods: Enhancers used were eugenol, limonene, basil oil, urea and SLS (sodium lauryl sulphate). Polymer used was chitosan and PEG 400 used as 
a plasticizer. Transdermal Films were prepared by using solvent casting method. FTIR and DSC were studied to assess any interaction between the 
drug and polymers. Films were evaluated for Physico-chemical Characteristics like thickness, weight variation, folding endurance, moisture loss, 
moisture absorption and drug content. In vitro skin permeation studies were performed using Keshary chien cell For 24 h across rat skin. 
Results: Chitosan was found to be a suitable polymer for matrix formation. 3.5% w/w was used to optimize to formulate transdermal patches. 1.5% 
of total solution v/v lactic acid was used for dissolution of chitosan. 2.5%v/v of total solution PEG 400 was used to provide plasticity and 
smoothness to the patches. From the evaluation of patches formulation, F10 containing Basil oil as penetration enhancer in the concentration of 
1.5% v/v was found to be best among all batches because of its consistent release rate For 24 h and extent of drug release was 85.20%. It can be 
concluded that naturally occurring volatile oils i.e., terpenes appear acceptable permeation enhancer and shows the best permeation across skin as 
indicated by high percutaneous enhancement ability. 
Conclusion: The developed transdermal patches are stable, non-irritating, and had increased efficacy of metoprolol and therefore had a good 
potential for hypertension treatment. 
Keywords: Transdermal drug delivery system, Chitosan, PEG 400, Penetration Enhancers, Basil oil, Limonene, Eugenol, Urea, Sodium lauryl sulphate 




Transdermal patches are pharmaceutical preparation, which 
delivers drugs directly into the systemic circulation after passing 
through the skin barrier [1]. It is convenient for the delivery of drugs 
having short biological half-life. 
Transdermal patches are easy to remove and apply. This approach 
of drug delivery is more pertinent in case of chronic disorders such 
as hypertension, which require long term dosing to maintain 
therapeutic drug concentration [2]. 
Transdermal delivery of therapeutic agents has been used 
successfully for several decades. In 1981, the first transdermal 
patch; Transderm Scop was developed by Alza Followed by 
Transderm Nitro [3]. Many other patches were introduced as motion 
sickness (hyoscine), cardiovascular disease (clonidine and 
nitroglycerin), Chronic pain (fentanyl), smoking cessation (nicotine), 
hormone replacement (levonorgestrel) [4]. 
Transdermal delivery of cardiovascular drugs offer several 
advantages as avoiding hepatic first-pass metabolism, maintaining 
constant blood level for a longer period resulting in a reduction of 
dosing frequency, improved bioavailability, decreased 
gastrointestinal irritation and improved patient compliance [5]. 
More than 35 TDDS products have now been approved for sale in US 
and approximately 16 active ingredients are approved for use in 
TDDS products globally. Global burden of disease study reported 
that there were 5.2 million deaths from cardiovascular diseases in 
economically developed countries and 9.1 million deaths from the 
same cause in developing countries. Hypertension is directly 
responsible for 57% of all stroke deaths in India [6]. 
In the present study, we aimed to deliver cardioselective beta-
blocker, metoprolol tartrate used for the treatment of mild and 
moderate hypertension and also for long term management of 
angina pectoris. Metoprolol tartrate has a bioavailability of 40-50% 
in oral dosage forms and the half-life is 3 to 7 h. This makes frequent 
dosing necessary to maintain therapeutic blood levels of the drug for 
long term treatment. Therefore, metoprolol tartrate is ideal drug 
candidate for transdermal drug delivery [7]. 
In the present investigation, the effort has been made to enhance the 
bioavailability of metoprolol tartrate for the treatment of 
hypertension as well as angina pectoris by using various natural 
permeation enhancers such as basil oil, limonene, eugenol, urea and 
sodium lauryl sulphate. The previous studies had utilized synthetic 
agents but in this study natural permeation enhancers are also being 
explored for the bioavailability enhancement of metoprolol tartrate. 
Oral metoprolol tartrate has a short elimination half-life (2-3 h), and 
low bioavailability undergoes extensive first-pass metabolism and 
frequent dosing. The aim of the present investigation was to 
formulate, develop and evaluate metoprolol tartrate transdermal 
patches using various synthetic and natural penetration enhancers. 
MATERIALS AND METHODS 
Materials 
Metoprolol tartrate was a gift sample from Ctx life science, Gujarat, 
India. Eugenol, limonene, sodium lauryl sulphate (sls), urea and basil 
oil from Central drug house. Chitosan has been received from Hi 
media. Other chemical and reagents were of analytical grades.  
Animals  
Wistar albino rats 150–200 g, and immature female wistar albino 
rats of 21–23 d old (40–60 g) were used in this study. They were 
procured from animal house, Amity Institute of Pharmacy, Amity 
University, Noida, UP. The animals were acclimatized for ten days 
under laboratory conditions. They were housed in polypropylene 
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cages and maintained at 27 °C±2 °C, relative humidity 65±10% 
under a 12-hour light/dark cycle. The animals were fed with rodent 
pellet diet and water ad libitum the protocol was approved by the 
Institutional Animal Ethics Committee (IAEC) and carried out in 
accordance with the Indian National Science Academy Guidelines for 
the use and care of animals. Animal skin was obtained from the 
animal house of Amity Institute of Pharmacy after CPCEA approval 
no. CPCSEA/AIP/2014/002.  
Each experimental group had a separate set of animals and care was 
taken to ensure that animals used for one response were not 
employed elsewhere. Animals were habituated to laboratory 
conditions for 48 h prior to an experimental protocol which 
minimizes any nonspecific stress. 
Methods 
Determination of melting point and solubility studies 
The melting point of the drug was determined by using Thieles tube 
method. The solubility of drug was determined after shaking the 
saturated solution of drug for 2 h at 25 ° C in water, chloroform, 
ethanol, acetone, and ether respectively. 
FTIR analysis 
FTIR spectra of pure drug and optimized formulation were obtained 
by FTIR spectrophotometer. 
Differential scanning calorimetry 
The DSC of the pure drug, polymer and physical mixture of drug-
polymer at 1:1 was carried out. 
UV analysis 
The aqueous solutions of the pure drug and the patches containing 
metoprolol tartrate were filtered through whatmann filter paper 
and scanned for UV absorption between 200 and 400 nm [8]. 
Development of transdermal films 
Solvent Casting method was used for the formulation of polymer 
matrix. The chitosan was weighed accurately as 3.5% w/w total 
solution. Chitosan was transferred to 20 ml beaker and lactic acid 
1.5% v/v of polymer was used to solubilize the chitosan. Beaker is 
kept on magnetic stirrer at a moderate speed to obtain a 
homogeneous mixture. PEG 400 2.5% was used as plasticizer and 
transferred to beaker containing chitosan. Metoprolol tartrate and 
enhancers were added to the solution. Solution was made up to 18 
ml with solvent and kept for 24 h to obtain homogeneous mixture of 
polymer, plasticizer and drug. After 24 h solution was transferred to 
teflon mould and was kept in oven at 40 °C overnight. After 24 h 
patches were scratched from mould. The patches thus formed were 
evaluated further for various parameters. The films were then 
packed in aluminum foil and stored in a desiccator until use at RH 
40% and temperature 20 °C [9]. 
 
Table 1: Composition of metoprolol transdermal drug delivery systems 
Formulation code  Drug   Polymer  Solvent  Plasticizer  Penetration enhancer 
Metoprolol tartrate (mg) Chitosan (mg) Lactic acid (ml) PEG 400 (ml) 
F1 360 630 0.27 0.45  _ 
F2 360 630 0.27 0.45 Limonene (0.5% v/v) 
F3 360 630 0.27 0.45 Limonene (1% v/v) 
F4 360 630 0.27 0.45 Limonene (1.5% v/v) 
F5 360 630 0.27 0.45 Eugenol (0.2%v/v) 
F6 360 630 0.27 0.45 Eugenol (0.5% v/v) 
F7 360 630 0.27 0.45 Eugenol (1%v/v) 
F8 360 630 0.27 0.45 Basil oil (0.5% v/v) 
F9 360 630 0.27 0.45 Basil oil (1% v/v) 
F10 360 630 0.27 0.45 Basil oil (1.5% v/v) 
F11 360 630 0.27 0.45 Urea (1% w/w) 
F12 360 630 0.27 0.45 Urea (2% w/w) 
F13 360 630 0.27 0.45 Urea (3% w/w) 
F14 360 630 0.27 0.45 SLS (0.5% w/w) 
F15 360 630 0.27 0.45 SLS (0.75% w/w) 
F16 360 630 0.27 0.45 SLS(1%w/w) 
 
Physico-chemical evaluation of prepared transdermal patches 
Weight variation 
Weight variation was determined by individually weighing randomly 
selected patches with the help of electronic balance. The average 
weight of a film and its standard deviation was calculated [10]. 
Folding endurance 
The folding endurance would be defined as the number of folds 
required to break any polymeric Film. The folds on the patch have to 
be made at the same point, till it breaks. It was measured manually by 
repeatedly folding the patch at the same place till it broke. The number 
of folds a patch can sustain will dictate its folding endurance [11]. 
Percentage of moisture loss 
The film was weighed accurately and placed in a desiccator 
containing 100 ml of saturated solution of calcium chloride (79.50% 
RH). After 3 d, the film was taken out and weighed, the percentage of 
moisture uptake was determined from the following formula 
Percentage of moisture loss = (X-Y/Y) × 100 
Where, X = initial weight, Y = final weight …………………………… 
Percentage of moisture content 
[12] 
The prepared patches are to be weighed individually and to be kept 
in desiccators containing fused potassium chloride (90%) at room 
temperature for 24 h. After 24 h the patches are to be reweighed and 
the percentage moisture content was determined from the following 
formula 
Percentage of moisture content = (X-Y/Y) × 100 
Where, X = initial weight, Y = final weight ………………… [13] 
Drug content 
The patches (1.6 cm2
Thickness 
) were cut and added to the beaker containing 
100 ml of phosphate buffer of pH 7.4. The medium was stirred with 
a magnetic bead. The contents were filtered using whatmann filter 
and the filtrate was examined for the drug content against the 
solution consisting of placebo patches spectrophotometrically at the 
wavelengths at which calibration curve has been plotted. The 
experiment was repeated to validate [14]. 
The thickness of transdermal patches was measured at three different 
places using a micrometer and the average value were calculated. 
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Longitudinal strips were cut out from the prepared medicated patch, 
the lengths of each strip were measured and then variation in the 
lengths due to the non-uniformity in flatness was measured. 
Flatness was calculated by measuring the construction of strips and 
a zero percent constriction is equal to a hundred percent flatness. 
Percentage of constriction = (I1-I2) I2 × 100 
Where, I1= initial length of each strip and 
I2
An in vitro permeation study was carried out by using keshary-chien 
diffusion cell. Hair from the abdominal region was removed 
carefully; the skin was thoroughly cleaned with distilled water to 
remove any adhering tissues or blood vessels, equilibrated for an 
hour in phosphate buffer pH 7.4 before starting the experiment. 
Diffusion cell was filled with a diffusion medium and placed on a 
magnetic stirrer with a small magnetic bead for uniform distribution 
of the diffusing. The temperature of the cell was maintained at 
37±0.5 °C using a thermostatically controlled heater. The isolated rat 
skin piece was mounted between the compartments of the diffusion 
cell, with the epidermis facing upward into the donor compartment. 
A sample volume of the definite volume was removed from the 
receptor compartment at regular intervals and an equal volume of 
fresh medium is to be replaced. Samples are analyzed spectro-
photometrically at wavelength 275 nm [16]. 
= final length of each strip …………………… [15] 
In vitro skin permeation studies 
In vitro drug release studies 
USP apparatus V paddle over disc method was used for assessment 
of the release of the drug from the prepared patches. A patch of 
known thickness was cut into definite shape, weighed and fixed over 
a glass plate with an adhesive. The paddle was then set at a distance 
of 2.5 cm from the glass plate and operated at a speed of 50 rpm. 
Samples were withdrawn at appropriate time intervals up to 24 h 
and analyzed by UV spectrophotometer. 
Percentage of drug release was calculated using the following Formula:  
Percentage drug release= Da/Dt ×100 
Where Da= amount of drug released 
Dt= amount of drug in the patch ……………… [17] 
Preliminary stability study of the optimized polymer matrix 
The fabricated patches were properly packed in aluminum foil and 
kept stability studies at the following temperature and relative 
humidity (RH) for one month at 25 C and 65% RH [18]. 
 
 
Fig. 2: FTIR of metoprolol tartrate 
 
 
Fig. 3: FTIR of transdermal patches 
 
RESULTS AND DISCUSSION 
Investigation of physicochemical compatibility of drug and 
polymer 
The physicochemical compatibility between the drugs and 
polymers used in the patches was studied by using differential 
scanning calorimetry (DSC). The sample was heated between 30 °C 
and 300 °C at the rate of 10 °C/min in an atmosphere of nitrogen 
(20 ml/min). The thermograms obtained for the drug, polymers, 
physical mixture of drugs with polymers and formulation (patch) 
were compared. 
The pure metoprolol tartrate peak was obtained at 125.8 °C. The 
DSC results suggest that the drug and polymers are compatible as 
found in fig. 1. 
Drug-polymer interaction studies  
FTIR spectroscopy  
The drug was characterized by FTIR spectroscopy. The spectrum 
was recorded using FTIR Spectrophotometer (Agilent). The scanning 
range was 4000 to 600 cm-1. The spectrum of Metoprolol tartrate is 
shown in fig. 2. 
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Fig. 1: DSC of metoprolol tartrate 
 
 
Fig. 2: FTIR of metoprolol tartrate 
 
FTIR spectra of pure Metoprolol Tartrate, chitosan, PEG 400, lactic 
acid and physical mixtures of these excipients with the drug were 
recorded on Agilent FTIR spectrophotometer. The instrument was 
operated under dry air purge and the scans were collected with the 
resolution of 4 cm-1 over the region 4000-400 cm-1. The scans were 
evaluated for presence of principle peaks of drug, shifting and 
masking of drug peaks and appearance of new peaks due to polymer 
interaction, shown in fig. 3. 
 
 
Fig. 3: FTIR of transdermal patches 
 
Physicochemical characterization of patches 
Chitosan 3.5% w/w in combination with 1.5% v/v lactic acid and 
PEG 400 along with varying concentration of penetration enhancers 
(natural as well as synthetic) were used for the formulation of 
transdermal films in the ratios as depicted in table 1. 
The results of the physicochemical characterization of the patches 
are shown in table 2. The weights ranged between 426 mg and 526 
mg, which indicates that different batches’ patch weights were 
relatively similar. Good uniformity of drug content among the 
batches was observed with all formulations and ranged from 
78.09% to 94.25%. The results indicate that the process employed 
to prepare patches in this study was capable of producing patches 
with uniform drug content and minimal patch variability. The 
flatness study showed that all the formulations had the same strip 
length before and after their cuts, indicating 100% flatness as 
depicted in table 2. 
Thus, no amount of constriction was observed; all patches had a 
smooth, flat surface; and that smooth surface could be maintained 
when the patch was applied to the skin. Folding endurance test 
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results indicated that the patches would not break and would 
maintain their integrity with general skin folding when applied. The 
folding endurance was found to be best in the patches containing 
basil oil as penetration enhancers as depicted in table 2. 
The moisture content of the prepared formulations was low, which 
could help the formulations remain stable and reduce brittleness 
during long term storage. The moisture uptake of the formulations 
was also low, which could protect the formulations from microbial 
contamination and reduce bulkiness. 
The moisture loss varied with different penetration enhancers. It 
was found that batches containing basil oil as penetration enhancers 
were best in terms of moisture loss since they had minimum water 
loss. The moisture loss was lowest in the patches without 
penetration enhancers as depicted in table 2. 
 




















F1 198±2.21 426±0.005 2.23±0.02 4.0±0.005 78.09±0.0432 100 0.53±0.007 
F2 180±2.23 523±0.004 4.92±0.07 3.59±0.061 80.66±0.023 100 0.52±0.017 
F3 189±2.20 521±0.002 3.62±0.03 5.1±0.025 88.12±0.029 100 0.53±0.010 
F4 190±2.27 526±0.002 4.71±0.05 6.21±0.021 89.67±0.039 100 0.55±0.016 
F5 188±2.36 524±0.003 2.94±0.06 4.18±2.21 80.18±0.051 100 0.53±0.015 
F6 195±2.78 520±0.001 3.28±0.02 6.12±1.98 87.20±0.042 100 0.51±0.012 
F7 191±3.21 522±0.001 5.23±0.04 8.49±1.99 90.32±0.051 100 0.55±0.015 
F8 200±1.23 510±0.002 2.12±0.03 4.08±0.22 82.03±0.005 100 0.52±0.018 
F9 193±1.45 498±0.003 3.72±0.01 3.07±0.12 91.53±0.023 100 0.55±0.016 
F10 203±1.89 493±0.002 1.28±0.03 3.02±0.22 94.25±0.09 100 0.54±0.019 
F11 172±2.22 499±0.004 2.52±0.05 4.2±0.006 89.20±0.028 100 0.53±0.013 
F12 185±2.34 500±0.006 3.89±0.06 2.5±0.002 90.15±0.02 100 0.55±0.015 
F13 187±3.21 497±0.002 4.50±0.02 3.23±0.005 89.25±0.024 100 0.56±0.012 
F14 197±2.10 495±0.001 3.01±0.05 4.82±0.281 88.10±0.0432 100 0.52±0.016 
F15 196±2.45 494±0.003 5.64±0.02 2.28±0.22 90.12±0.044 100 0.54±0.019 
F16 192±2.98 496±0.003 4.93±0.03 3.69±0.226 86.99±0.042 100 0.55±0.011 
*All values are expressed as mean±SD (n = 10). 
 
Table 3: In vitro cumulative drug release of metoprolol transdermal drug delivery systems 
S. No. Formulation code Cumulative percentage drug release  
1 F1 58.03±1.90 
2 F2 69.86±0.90 
3 F3 72.5±1.99 
4 F4 79.26±1.09 
5 F5 69.12±1.23 
6 F6 75±1.98 
7 F7 80.12±1.54 
8 F8 80.12±1.54 
9 F9 75.5±1.90 
10 F10 85.201±0.30 
11 F11 60.96±1.19 
12 F12 72.5±1.98 
13 F13 75.22±1.67 
14 F14 58.07±1.65 
15 F15 65.521±1.23 
16 F16 60.25±0.45 
*All values are expressed as mean±SD (n = 10) 
 
 
Fig. 4: In vitro skin permeation profile of metoprolol from transdermal patches, data are mean±SE (n=6) 
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In vitro skin permeation studies 
The in vitro skin permeation studies were carried out using keshary 
chien cell for a period of 24 h. The patches were 15 cm2 
CONCLUSION 
in area and 
were prepared by solvent casting method by using PEG 400 as a 
plasticizer. In order to know whether the patches would release 
drug in desired fashion in vitro permeation studies in Keshary chien 
cell was carried out. Along with that, diffusion studies were also 
evaluated in phosphate buffer pH7.4 [23-25] The in vitro permeation 
of various formulations were the in vitro release of formulations 
from F1 to F16 were found in the range of 58.03% to 80.20%, as 
depicted in table 3. From the evaluation of patches formulation, F10 
containing basil oil as penetration enhancer in the concentration of 
1.5% v/v was found to be best among all batches because of its 
consistent release rate for 24 h and extent of drug release was 
85.20% as depicted in fig. 4 and table 3. The formulation F10 have 
achieved highest drug release as compared to other polymers. 
The patches are containing basil oil as penetration enhancer were 
best in terms of physicochemical properties as well as drug release. 
The formulation F10 was found to be best among all batches 
because of its consistent release rate for 24 h, and extent of drug 
release was 85.20%. It can be concluded that naturally occurring 
volatile oils i.e., terpenes appear acceptable permeation enhancer 
and shows the best permeation across skin as indicated by high 
percutaneous enhancement ability. 
The developed transdermal patches are stable, non-irritating and 
had increased efficacy of metoprolol and therefore had a good 
potential for hypertension treatment. However, pharmacodynamics 
and pharmacokinetic evaluation of these systems in human 
volunteers is necessary to confirm these findings. 
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